ER Pharmatech Co.,LTD

Loratinib

• Category :

  Pharmaceuticals and Biochemicals

• Synonyms :

  PF0643922;Lorlatinib;PF-06463922;(10R)-7-Amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile;Lorlatinib,PF-06463922;PF-06463922, Lorlatinib;(R)-26-amino-55-fluoro-11,4,7-trimethyl-6-oxo-11H-3-oxa-7-aza-2(3,5)-pyridina-1(4,3)-pyrazola-5(1,2)-benzenacyclooctaphane-15-carbonitrile;

• CAS NO :

  1454846-35-5

• EC NO :

• Molecular Formula :

• Molecular Weight :

• Main Specifications :

  99%

• Packing :

  As customer request

• Product description :

  Product Name: Lauratinib Synonyms: Loratinib (PF-06463922);Lauratinib;PF-06463922, Lorlatinib;PF-06463922 CAS: 1454846-35-5 MF: C21H19FN6O2 MW: 406.4129632 EINECS: 813-704-5 Assay: 99% Uses: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that promotes cell proliferation and blocks apoptosis. PF-06463922 is an ATP-competitive, selective inhibitor of ALK (Ki = < 0.07 nM) and c-Ros oncogene 1 (ROS1, Ki = 0.7 nM). It has strong activity against all known ALK and ROS1 mutants identified in patients, including the EML4-L1196M mutant of ALK (Ki = < 0.02 nM). PF-06463922 is orally available, displaying inhibition of ALK phosphorylation and antitumor efficacy in a xenograft model expressing EML4-L1196M ALK. It demonstrates efficient blood-brain barrier penetration, produces brain tumor regression in mice harboring EML4-ALK tumors, and increases overall survival.

• Uses :

  Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that promotes cell proliferation and blocks apoptosis. PF-06463922 is an ATP-competitive, selective inhibitor of ALK (Ki = < 0.07 nM) and c-Ros oncogene 1 (ROS1, Ki = 0.7 nM). It has strong ac

• Molecular Structure :